Navigation Links
Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
Date:5/18/2012

ALLEGAN, Mich., May 18, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Lansoprazole capsules (15 mg). Shipments of product to customers have already begun. 

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

This new product for the U.S. store brand market is bioequivalent to Novartis' Prevacid® 24HR capsules (15 mg) and is indicated for the treatment of frequent heartburn, which occurs two or more days in a week. Sales for Prevacid OTC were approximately $220 million.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This is another example of Perrigo's continued leadership and commitment to bring key new products to the store brand OTC market. Perrigo continues to be focused on our mission of making quality healthcare more affordable for consumers. We are pleased to be in a position to bring this important new product to market – for our retail and wholesale customers' store brand product portfolios and to U.S. consumers, who will realize considerable savings now that they can purchase a high quality, value priced alternative to the national brand."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).'/>"/>

SOURCE Perrigo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
5. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
6. Perrigo Company Announces Dividend Increase
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
9. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
10. Perrigo Company To Present at the Sidoti Emerging Growth Conference
11. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... YORK , Oct. 30, 2014  The number ... States is growing steadily, thanks to drug ... as a result of the economic downturn, retail clinic ... a year of opportunities, as the number of retail ... researcher,s report, Retail Clinics Market Overview and 2014 ...
(Date:10/30/2014)... Oct. 30, 2014 Molecular Profiles Ltd., a ... ) and Maryland -based Xceleron have ... efficiency during clinical development that will be launched at ... week. This partnership extends Molecular Profiles, new ... launched earlier this month. The company also has complementary ...
(Date:10/30/2014)... Oct. 30, 2014  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced an upcoming ... drug candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates ... be given by Sant P. Chawla , ... and principal investigator of the Company,s ongoing global, ...
Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
... April 26 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced ... calls focused on the drugs in Isis, development pipeline.  The second call of ... Wednesday, April 28, 2010 at 12:00 p.m. ET .  This ... , , ...
... , TITUSVILLE, N.J. , April 26 The Court ... Pediatrics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., to overturn a 2009 decision ... for CONCERTA (methylphenidate HCl) Extended-Release Tablets CII is invalid and not infringed ... , In ...
Cached Medicine Technology:Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28 2Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28 3CONCERTA(R) Patent Appeal Denied 2CONCERTA(R) Patent Appeal Denied 3
(Date:10/30/2014)... October 30, 2014 Paramount Rx, a ... is increasing efforts to help people save money through ... to increase for prescription drugs in the new health ... and resources to bridge the relationship between consumers, businesses ... the biggest challenges people face today with medical costs ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... prostate cancer who also have certain heart problems may increase ... study suggests. , , The therapy in question is called androgen ... levels of male hormones to prevent the growth of cancer ... this hormone therapy was linked to triple the risk of ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... in Liberia -- one of three West African nations ravaged ... officials said Wednesday. Dr. Bruce Aylward, WHO,s assistant director ... burials in Liberia and no increase in laboratory-confirmed cases. He ... tame the epidemic may be making some progress, The ...
(Date:10/30/2014)... IL (PRWEB) October 30, 2014 Dr. Joseph ... a new website for his practices; OB GYN in ... IL . This website contains important information about each ... as well as downloadable patient forms in English and Spanish. ... and the service pages on the website provide Dr. Furlin’s ...
(Date:10/30/2014)... Francisco, California (PRWEB) October 30, 2014 ... billion by 2020, according to a new study by ... coupled with surging demand for sugar and fat free ... to augment the demand for prebiotics over the forecast ... http://www.grandviewresearch.com/industry-analysis/prebiotics-market , Food & beverage was the ...
Breaking Medicine News(10 mins):Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5
... that men who have undergone vasectomy may be at ... study was published in Cognitive and Behavioural Neurology. ... of this, 25 developed a dementia called primary progressive ... the chief scientist of this study Sandra Weintraub, this ...
... have multiple sclerosis (MS) for 10 years and have few of ... “benign MS” and that their symptoms will likely not ever occur ... study shows that unfortunately this may not be correct. ... of those whose MS was benign at 10 years, according to ...
... test that can distinguish between a pair of nearly ... treatment. ,Their report is published this week ... the National Academy of Sciences. ,"This simple ... quickly implemented in the clinic to benefit patients by ...
... appreciable decline in the number of women dying at childbirth ... Gautemala and Morocco that have managed to arrest this trend. ... of maternal deaths per 100,000 live births, was 301 in ... 70,000 women die every year in India but UNICEF says ...
... An anti-smoking campaign in Colorado that involves door-to-door ... of thousands of dollars and "is raising questions ... cessation efforts among minorities, the Denver Rocky Mountain ... approved a tobacco tax increase, which so far ...
... a national study, patients being treated for a ... Shore University Hospital// (NSUH) and Long Island Jewish ... arsenic compound, coupled with standard chemotherapy treatments, significantly ... newly-diagnosed acute promyelocytic leukemia, or APL, and participated ...
Cached Medicine News:Health News:A New Two-gene Test to Discern Similar Gastrointestinal Cancers 2Health News:India Lags Far Behind in Controlling Maternal Deaths 2Health News:Arsenic Compound Effective in Treating Rare Leukemia 2Health News:Arsenic Compound Effective in Treating Rare Leukemia 3
... to Z Drug Facts produced by ... on thousands of medications. It provides ... effect, drug interactions, patient information and ... reference for physicians, students, residents, pharmacists, ...
Very concise book answering the question: "I've got a diagnosis, which drugs do I use?". All 15 chapters written by highly skilled US specialists...
... with Integrated Calculators, based on Davis's Drug ... advance in drug reference. DDGNIC contains the ... Guide (9th Edition) and has integrated calculation ... product merges many of the advantages of ...
Allows health professionals to answer consumers' questions regarding safety issues concerning possible drug-herb and drug-food interactions....
Medicine Products: